[PDF][PDF] Pricing of monoclonal antibody therapies: higher if used for cancer
I Hernandez, SW Bott, AS Patel, CG Wolf… - Am J Manag …, 2018 - ajmc.s3.amazonaws.com
I Hernandez, SW Bott, AS Patel, CG Wolf, AR Hospodar, S Sampathkumar, WH Shrank
Am J Manag Care, 2018•ajmc.s3.amazonaws.comStudy Design We identified all indications approved by the FDA for mAbs from 1997 to 2016
using the FDA website. 9 After excluding radioactive mAb–indication combinations (n= 1),
antidotes (n= 1), and those approved for diagnostic purposes (n= 3), withdrawn from the
market by 2016 (n= 2), or not available to the public for other reasons (n= 2), our sample
included 107 unique mAb–indication combinations (eAppendix Table 1 [eAppendices
available at ajmc. com]). From the
using the FDA website. 9 After excluding radioactive mAb–indication combinations (n= 1),
antidotes (n= 1), and those approved for diagnostic purposes (n= 3), withdrawn from the
market by 2016 (n= 2), or not available to the public for other reasons (n= 2), our sample
included 107 unique mAb–indication combinations (eAppendix Table 1 [eAppendices
available at ajmc. com]). From the
Study Design
We identified all indications approved by the FDA for mAbs from
1997 to 2016 using the FDA website. 9 After excluding radioactive mAb–indication combinations (n= 1), antidotes (n= 1), and those approved for diagnostic purposes (n= 3), withdrawn from the market by 2016 (n= 2), or not available to the public for other reasons (n= 2), our sample included 107 unique mAb–indication combinations (eAppendix Table 1 [eAppendices available at ajmc. com]). From the
ajmc.s3.amazonaws.com